The pattern-recognition receptor NOD1 promotes production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts
Arthritis & Rheumatism,

Yokota K et al. – NOD–1 is strongly expressed in different cell types in the synovial tissue of patients with rheumatoid arthritis (RA). These results indicate that NOD–1, either alone or interacting with other inflammatory mediators, can play an important role in the chronic and destructive inflammation of the joints in RA.

Methods
  • Expression of NOD–1 was analyzed by immunohistochemistry in synovial tissue from RA patients, psoriatic arthritis patients, gout patients, and osteoarthritis (OA) patients.
  • RASFs and human monocyte–derived macrophages (HMDMs) were stimulated with L–alanyl–γ–D–glutamyl–meso–diaminopimelic acid, palmitoyl–3–cysteine–serine–lysine–4, poly(I–C), lipopolysaccharide, heat–inactivated bacteria, tumor necrosis factor α (TNF α), or interleukin–1 β (IL–1 β).
  • Expression levels of IL–6, CCL5, matrix metalloproteinases (MMPs), NODs, and TLRs were measured by real–time reverse transcription–polymerase chain reaction and/or enzyme–linked immunosorbent assay.
  • NOD–1 and NOD–2 were silenced with target–specific small interfering RNA.
  • Phosphorylation of IL–1 receptor–associated kinase 1 (IRAK–1) was measured by Western blotting.

Results
  • Expression of NOD–1 protein was significantly increased in RA synovium compared to OA synovium.
  • The basal expression of NOD–1 was similar in RASFs, OASFs, healthy control peripheral blood mononuclear cells, and healthy control HMDMs.
  • Stimulation of RASFs with TLR–3 up–regulated the expression of NOD–1.
  • Expression of IL–6, CCL5, MMPs, TLR–2, and NOD–2 was significantly up–regulated in RASFs by stimulation with the NOD–1 ligand.
  • A synergistic effect on IL–6 production was observed in cells stimulated with NOD–1 and TLR–2 ligands or NOD–1 and TLR–4 ligands.
  • Silencing of NOD–1, but not NOD–2, decreased the levels of IL–6 in RASFs after stimulation with TLR–2 and IL–1β, and blocked the phosphorylation of IRAK–1.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Rheumatology Articles

1 Immune fault linked to disease University of Edinburgh College of Medicine News, December 1, 2014

2 A combination of celecoxib and famciclovir is efficacious in the treatment of fibromyalgia: Results of a phase IIa randomized, double-blind, placebo-controlled study American College of Rheumatology News, December 2, 2014    Clinical Article

3 The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: A systematic review and meta-analysis Lupus, November 26, 2014    Evidence Based Medicine    Review Article

4 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

5 Blood test could prevent medication trial and error for rheumatoid arthritis patients Mayo Clinic, November 18, 2014

6 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

7 Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Rheumatology, December 8, 2014    Clinical Article

8 Yearly treatment could slow osteoarthritis Monash University News, September 23, 2014

9 Ten common mistakes in the management of lupus nephritis American Journal of Kidney Diseases, January 3, 2014    Clinical Article

10 Tramadol and risk of hospitalization for hypoglycemia McGill University News, December 10, 2014

11 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

12 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

13 Lupus enteritis: Clinical characteristics and predictive factors for recurrence Lupus, December 4, 2014    Clinical Article

14 Safety and efficacy of ifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus American College of Rheumatology News, November 25, 2014

15 Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis International Journal of Rheumatic Diseases, December 11, 2014    Clinical Article

16 Fish consumption and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Research & Therapy, October 8, 2014    Evidence Based Medicine    Review Article

17 Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids Rheumatology, December 10, 2014    Clinical Article

18 Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial Annals of Rheumatic Diseases, November 10, 2014    Clinical Article

19 Electrical stimulation for pain relief in knee osteoarthritis: Systematic review and network meta-analysis Osteoarthritis and Cartilage , December 4, 2014    Evidence Based Medicine    Review Article

20 Current evidence on risk factors for knee osteoarthritis in older adults: A systematic review and meta-analysis Osteoarthritis and Cartilage , December 2, 2014    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List